{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:02Z","timestamp":1790089622018,"version":"4.0.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype for which neoadjuvant chemotherapy (NACT) is used for locally advanced (LA) disease. Patients with TNBC who experienced a pathologic complete response (pCR) following NACT have been found to have extended overall survival (OS) compared to patients with residual disease. Sparse data exist on the frequency and impact of pCR following NACT for TNBC in East Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients diagnosed with LA TNBC who received NACT between 2018 and 2022 at Moi Teaching and Referral Hospital in Eldoret, Kenya. After NACT, patients underwent mastectomy in which specimens were reviewed histologically as either pCR or residual disease in the breast and\/or axilla. Clinical data were analyzed using descriptive statistics and Kaplan-Meier methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-nine women with LA TNBC were included. Patient characteristics at diagnosis: Median age = 51\u2009years (IQR 44-60); T4 disease = 34 (49%); and nodal involvement = 62 (91%). Forty-six patients (67%) received anthracycline\/taxane-based chemotherapy with a median of 8 cycles (IQR 6-8), and 47 (68%) underwent mastectomy, with only 7% achieving pCR. Assuming all lost to follow-up died, the worst-case OS was 83% and 56% at 1 and 2\u2009years, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this LMIC setting, patients who presented with LA TNBC had lower pCR rates following NACT than observed in high-income countries. Our findings highlight the critical need for innovative, cost-effective programs focused on early detection of breast cancer, linkage of care, and delivery of more effective therapies to improve outcomes in the region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag325","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:15:51Z","timestamp":1786706151000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-8833","authenticated-orcid":false,"given":"Hussain I","family":"Rangoonwala","sequence":"first","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]},{"name":"Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Busakhala","sequence":"additional","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]},{"name":"Moi University College of Health Sciences , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Kiprono","sequence":"additional","affiliation":[{"name":"KEMRI Wellcome Trust , Kilifi 80108,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loice","family":"Sitienei","sequence":"additional","affiliation":[{"name":"Moi University College of Health Sciences , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Chesori","sequence":"additional","affiliation":[{"name":"Moi Teaching and Referral Hospital , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Niemeyer","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Sabul","sequence":"additional","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-4427","authenticated-orcid":false,"given":"Jesse","family":"Opakas","sequence":"additional","affiliation":[{"name":"Moi Teaching and Referral Hospital , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ngelel","sequence":"additional","affiliation":[{"name":"Moi Teaching and Referral Hospital , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-2354","authenticated-orcid":false,"given":"Felix","family":"Pabon-Rodriguez","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]},{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kibet","family":"Keitany","sequence":"additional","affiliation":[{"name":"Moi Teaching and Referral Hospital , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Melly","sequence":"additional","affiliation":[{"name":"Kenya National Cancer Institute, Nairobi Kenya, 00100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hunter-Squires","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-883X","authenticated-orcid":false,"given":"Kathy D","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kisilu","sequence":"additional","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Loehrer","sequence":"additional","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]},{"name":"Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Morgan","sequence":"additional","affiliation":[{"name":"Academic Model for Providing Access to Healthcare (AMPATH) , Eldoret 30100,","place":["Kenya"]},{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota School of Medicine, Minneapolis, MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026092210513034500_oyag325-B1","doi-asserted-by":"publisher","first-page":"001","DOI":"10.4172\/2161-1041.S2-001","article-title":"Triple negative breast Cancer - an overview","volume":"2013","author":"Aysola","year":"2013","journal-title":"Hereditary Genet"},{"key":"2026092210513034500_oyag325-B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1634\/theoncologist.2011-S1-61","article-title":"Molecular stratification of triple-negative breast cancers","volume":"16","author":"Perou","year":"2011","journal-title":"Oncologist"},{"key":"2026092210513034500_oyag325-B3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jclinpath-2012-201361","article-title":"Therapeutic targets in triple negative breast cancer","volume":"66","author":"O\u2019Toole","year":"2013","journal-title":"J Clin Pathol"},{"key":"2026092210513034500_oyag325-B4","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"2026092210513034500_oyag325-B5","doi-asserted-by":"publisher","first-page":"e055735","DOI":"10.1136\/bmjopen-2021-055735","article-title":"Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis","volume":"12","author":"Hercules","year":"2022","journal-title":"BMJ Open"},{"key":"2026092210513034500_oyag325-B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/GO.20.00398","article-title":"Receptor-defined breast cancer in five east African countries and its implications for treatment: systematic review and meta-analysis","volume":"7","author":"Popli","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B7","doi-asserted-by":"publisher","first-page":"e2300135","DOI":"10.1200\/GO.23.00135","article-title":"Breast cancer phenotypes in Africa: a scoping review and meta-analysis","volume":"9","author":"Onyia","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B8","doi-asserted-by":"publisher","first-page":"e000829","DOI":"10.1136\/esmoopen-2020-000829","article-title":"Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique","volume":"5","author":"Brand\u00e3o","year":"2020","journal-title":"ESMO Open"},{"key":"2026092210513034500_oyag325-B9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"2026092210513034500_oyag325-B10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in Early- Stage Triple-Negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092210513034500_oyag325-B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12905-024-03114-y","article-title":"Prognostic factors and overall survival of breast cancer in Benin: a hospital-based study","volume":"24","author":"Gnangnon","year":"2024","journal-title":"BMC Womens Health"},{"key":"2026092210513034500_oyag325-B12","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.bulcan.2025.05.009","article-title":"Prognostic factors of breast cancer and survival in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"112","author":"Parent\u00e9","year":"2025","journal-title":"Bull Cancer"},{"key":"2026092210513034500_oyag325-B13","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/jnci\/djaf213","article-title":"Survival deficits in young women with breast cancer in Sub-Saharan Africa: the ABC-DO cohort","volume":"117","author":"Mo","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026092210513034500_oyag325-B14","doi-asserted-by":"publisher","first-page":"e1203","DOI":"10.1016\/S2214-109X(20)30261-8","article-title":"Breast cancer survival and survival gap apportionment in Sub-Saharan Africa (ABC-DO): a prospective cohort study","volume":"8","author":"McCormack","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2026092210513034500_oyag325-B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4314\/aas.v18i1.5","article-title":"Predicting response to neoadjuvant chemotherapy in women with locally advanced breast cancer in Kenya: utility of ki67","volume":"18","author":"Mogere","year":"2021","journal-title":"Ann Afr Surg"},{"key":"2026092210513034500_oyag325-B16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-018-4727-9","article-title":"Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations","volume":"170","author":"Clifton","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026092210513034500_oyag325-B17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejso.2019.11.498","article-title":"Neoadjuvant chemotherapy in patients with breast cancer: does response in the breast predict axillary node response?","volume":"46","author":"Morgan","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"2026092210513034500_oyag325-B18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10549-020-05889-8","article-title":"A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection","volume":"184","author":"Nietz","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026092210513034500_oyag325-B19","doi-asserted-by":"publisher","first-page":"e2200016","DOI":"10.1200\/GO.22.00016","article-title":"Relative dose intensity and pathologic response rates in patients with breast cancer and with and without HIV who received neoadjuvant chemotherapy","volume":"8","author":"Martei","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.11604\/pamj.2018.29.45.12523","article-title":"Descriptive study of triple negative breast cancer in Eastern Algeria","volume":"29","author":"Souad","year":"2018","journal-title":"Pan Afr Med J"},{"key":"2026092210513034500_oyag325-B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1472-6874-12-35","article-title":"Triple negative breast cancer in moroccan women: clinicopathological and therapeutic study at the national institute of oncology","volume":"12","author":"Rais","year":"2012","journal-title":"BMC Womens Health"},{"key":"2026092210513034500_oyag325-B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4314\/ejhs.v24i1.2","article-title":"Evaluation of clinical and pathological response after two cycles of neoadjuvant chemotherapy on sudanese patients with locally advanced breast cancer","volume":"24","author":"Alawad","year":"2014","journal-title":"Ethiop J Health Sci"},{"key":"2026092210513034500_oyag325-B23","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092210513034500_oyag325-B24","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase. Trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"2026092210513034500_oyag325-B25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet (London, England)"},{"key":"2026092210513034500_oyag325-B26","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092210513034500_oyag325-B27","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026092210513034500_oyag325-B28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/cancers12061404","article-title":"Neoadjuvant treatment for triple negative breast cancer: Recent progresses and challenges","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092210513034500_oyag325-B29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026092210513034500_oyag325-B30","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-18-0585","article-title":"Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel","volume":"24","author":"Sharma","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026092210513034500_oyag325-B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.abe1916","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in kenyan blood donors","volume":"371","author":"Uyoga","year":"2021","journal-title":"Science (New York, N.Y.)"},{"key":"2026092210513034500_oyag325-B32","author":"Ferlay","year":"2024"},{"key":"2026092210513034500_oyag325-B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00111","article-title":"Sentinel lymph node biopsy pathology and 2-Year postsurgical recurrence of breast cancer in kenyan women","volume":"4","author":"Brand","year":"2018","journal-title":"J Glob Oncol"},{"key":"2026092210513034500_oyag325-B34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-017-4511-2","article-title":"Ethnicity and breast cancer characteristics in Kenya","volume":"167","author":"Sayed","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026092210513034500_oyag325-B35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-016-2204-6","article-title":"Aggressive breast cancer in Western Kenya has early onset, high proliferation, and immune cell infiltration","volume":"16","author":"Sawe","year":"2016","journal-title":"BMC Cancer"},{"key":"2026092210513034500_oyag325-B36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.breast.2014.06.006","article-title":"Is breast cancer from Sub saharan africa truly receptor poor? Prevalence of ER\/PR\/HER2 in breast cancer from Kenya","volume":"23","author":"Sayed","year":"2014","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"2026092210513034500_oyag325-B37","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1245\/s10434-008-9900-7","article-title":"Poor hormone receptor expression in east african breast cancer: evidence of a biologically different disease?","volume":"15","author":"Bird","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2026092210513034500_oyag325-B38","first-page":"97","article-title":"Routine assessment of hormonal receptor and her-2\/neu status underscores the need for more therapeutic targets in kenyan women with breast cancer","volume":"28","author":"Nyagol","year":"2006","journal-title":"Anal Quant Cytol Histol"},{"key":"2026092210513034500_oyag325-B39","author":"Breast Cancer NCCN Harmonized Guidelines for Sub-Saharan Africa"},{"key":"2026092210513034500_oyag325-B40","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092210513034500_oyag325-B41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2026092210513034500_oyag325-B42","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026092210513034500_oyag325-B43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2026092210513034500_oyag325-B44","doi-asserted-by":"publisher","first-page":"e1589","DOI":"10.1002\/onco.13814","article-title":"Opportunities for improvement in the administration of neoadjuvant chemotherapy for T4 breast cancer: a comparison of the U.S. and Nigeria","volume":"26","author":"Romanoff","year":"2021","journal-title":"Oncologist"},{"key":"2026092210513034500_oyag325-B45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13053-023-00249-1","article-title":"Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer\u2014single hospital experience","volume":"21","author":"Sivina","year":"2023","journal-title":"Hered Cancer Clin Pract"},{"key":"2026092210513034500_oyag325-B46","doi-asserted-by":"publisher","first-page":"e2300187","DOI":"10.1200\/GO.23.00187","article-title":"Significance of pathologic response in patients with early and locally advanced breast cancer treated with neoadjuvant chemotherapy in a Middle-Income country. A Real-World historical cohort","volume":"10","author":"Mantilla","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B47","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.2217\/fon-2021-0530","article-title":"Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer","volume":"17","author":"Haiderali","year":"2021","journal-title":"Future Oncology (London, England)"},{"key":"2026092210513034500_oyag325-B48","doi-asserted-by":"publisher","first-page":"e2300093","DOI":"10.1200\/GO.23.00093","article-title":"Population-level access to breast cancer early detection and diagnosis in Nigeria","volume":"9","author":"Omisore","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B49","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.4102\/sajr.v22i2.1370","article-title":"Screening mammography with special reference to guidelines in South Africa","volume":"22","author":"Lipschitz","year":"2018","journal-title":"SA J Radiol"},{"key":"2026092210513034500_oyag325-B50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/ijmr.IJMR_2635_20","article-title":"Screening for breast cancer: Cost-effective solutions for low- & Middle-income countries","volume":"154","author":"Mishra","year":"2021","journal-title":"Indian J Med Res"},{"key":"2026092210513034500_oyag325-B51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13244-020-00905-3","article-title":"Do we still need breast cancer screening in the era of targeted therapies and precision medicine?","volume":"11","author":"Trimboli","year":"2020","journal-title":"Insights Imag"},{"key":"2026092210513034500_oyag325-B52","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1056\/NEJMsr1504363","article-title":"Breast-cancer screening\u2014viewpoint of the IARC working group","volume":"372","author":"Lauby-Secretan","year":"2015","journal-title":"New England J Med"},{"key":"2026092210513034500_oyag325-B53","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1002\/cnr2.1480","article-title":"Breast health awareness campaign and screening pilot in a kenyan county: findings and lessons","volume":"5","author":"Mwenda","year":"2022","journal-title":"Cancer Reports (Hoboken, N.J.)"},{"key":"2026092210513034500_oyag325-B54","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/JOP.091036","article-title":"Dose intensity in early-stage breast cancer: a community practice experience","volume":"5","author":"Bretzel","year":"2009","journal-title":"J Oncol Pract"},{"key":"2026092210513034500_oyag325-B55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 Years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ (Clinical Research ed.)"},{"key":"2026092210513034500_oyag325-B56","author":"Eib","year":"."},{"key":"2026092210513034500_oyag325-B57","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.3390\/ijerph20247190","article-title":"Remote symptom monitoring to enhance the delivery of palliative cancer care in Low-Resource settings: Emerging approaches from Africa","volume":"20","author":"Salako","year":"2023","journal-title":"IJERPH"},{"key":"2026092210513034500_oyag325-B58","doi-asserted-by":"publisher","first-page":"e2400557","DOI":"10.1200\/GO-24-00557","article-title":"Global equity in clinical trials: a pragmatic approach","volume":"11","author":"Rangoonwala","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"2026092210513034500_oyag325-B59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210513034500_oyag325-B60","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.2020.38.15_suppl.584","article-title":"Inhibiting fatty acid synthase in operable triple negative breast cancer","volume":"38","author":"Sardesai","year":"2020","journal-title":"JCO"},{"key":"2026092210513034500_oyag325-B61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2017.04.001","article-title":"Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice","volume":"79","author":"Schraa","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag325\/70651100\/oyag325.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag325\/70651100\/oyag325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag325\/70651100\/oyag325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:51:37Z","timestamp":1790088697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag325\/8761706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag325","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,14]]},"article-number":"oyag325"}}